newsfilter
← Earnings
Earnings Releases·

Xtant Medical — Third Quarter 2026 Earnings Summary

  • Financial Performance:

    • Total revenue was $24.3 million for the third quarter of 2026, a 27% year-over-year decrease from $33.3 million in Q3 2025 and a 5% increase from $23.0 million in Q2 2026.
    • Biologics revenue was $19.3 million, representing a 13% year-over-year increase from $17.1 million in Q3 2025 and an 11% increase from $17.4 million in Q2 2026; this figure includes $2.2 million from HEMOBLAST® Bellows sales.
    • Biologics product revenue excluding HEMOBLAST and products affected by wound care reimbursement grew 6% year-over-year and 8% quarter-over-quarter.
    • Gross margin was 56.3% in Q3 2026, down from 66.1% in Q3 2025, driven by a 670-basis-point impact from the cessation of high-margin wound care licensing revenue and a 360-basis-point impact from sales mix.
    • Operating expenses were $16.7 million in Q3 2026, down from $19.5 million in Q3 2025; General and administrative expenses decreased to $5.0 million from $7.1 million, while sales and marketing expenses decreased to $11.2 million from $11.7 million.
    • Net loss was $3.6 million ($0.03 per share) for Q3 2026, compared to net income of $1.3 million ($0.01 per diluted share) in Q3 2025.
    • Adjusted EBITDA was a loss of $1.5 million for Q3 2026, compared to a profit of $4.5 million in Q3 2025.
    • As of September 30, 2026, the company held $7.8 million in cash and cash equivalents, with $22 million in total indebtedness ($10.2 million debt and $11.8 million revolving credit facility borrowings) and $2.1 million of availability under the revolving credit facility.
    • Cash and cash equivalents decreased from $17.1 million as of December 31, 2025, to $7.8 million as of September 30, 2026.
  • Guidance and Future Outlook:

    • The company no longer expects to achieve its previously issued full-year 2026 guidance based on year-to-date performance.
    • No revised full-year 2026 financial guidance is being provided while the Board conducts its strategic review process.
    • Management expects cash and cash equivalents, plus availability under the revolving credit facility, to be sufficient to fund operations for at least the next 12 months.
  • Business Segments and Product Lines:

    • The year-over-year revenue decline is primarily attributed to the absence of $5.4 million in prior-year revenue from divested non-core Coflex/CoFix assets and international hardware business, and the absence of $5.5 million in prior-year wound care licensing revenue.
    • The biologics franchise is showing momentum with year-over-year and quarter-over-quarter growth.
    • Sales and marketing expense increases were partially offset by higher compensation expense related to increased sales headcount hired for the exclusive U.S. distribution agreement for HEMOBLAST.
  • Market and Competitive Landscape:

    • The company operates in the medical technology sector focusing on surgical solutions for spinal and orthopedic conditions, chronic and surgical wound care, and sports medicine.
    • The company holds an exclusive U.S. distribution agreement for HEMOBLAST.
  • Risks and Challenges:

    • The Board has initiated a strategic review process evaluating a broad range of alternatives, including operational improvements, capital structure changes, partnerships, restructurings, financings, acquisitions, dispositions, and business combinations, with no assurance of a specific outcome.
    • Risks include the possibility that the strategic review process may be suspended, modified, or terminated, and that any resulting action may not achieve anticipated benefits.
    • The company faces risks related to the success of the Dilon distribution arrangement and HEMOBLAST product, including potential termination or manufacturing non-performance.
    • Additional risks include the ability to sustain revenue growth in the biologics business, product sales mix changes, reimbursement environment changes, and compliance with debt covenants including minimum liquidity and net revenue covenants.
  • Management Commentary and Tone:

    • Stavros Vizirgianakis, Chairman of the Board, expressed disappointment with the financial performance, noting it was the second consecutive quarter missing guidance and described the shortfall as unacceptable.
    • The Board emphasized that directors have invested their own capital and includes a representative of the largest stockholder, aligning their interests with stockholders.
    • The Board's stated priorities are to improve execution, improve financial performance, and maximize stockholder value through the strategic review process.
    • Management remains encouraged by the momentum in the core biologics business and is committed to scaling this franchise during the review.
  • Other Key Points:

    • The Board has announced a board-led strategic review process to maximize stockholder value.
    • The company will not host a conference call or webcast to discuss the third quarter 2026 financial results.
    • A $5.0 million write-off of a distribution agreement deposit was recorded in operating expenses for the nine months ended September 30, 2026.
    • Proceeds from divestitures totaled $10.368 million for the nine months ended September 30, 2026.
    • The company has no preferred stock issued or outstanding.
Company
XTANT MEDICAL HOLDINGS INC
Sector
Healthcare
Industry
Medical Devices